Cargando…
Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows
BACKGROUND: The risk of cancer treatment‐related acute exacerbation (AE) in patients with lung cancer and mild interstitial lung disease (ILD) on imaging, classified as indeterminate for usual interstitial pneumonia (UIP), has not previously been clarified. METHODS: We retrospectively reviewed the c...
Autores principales: | Takahara, Yutaka, Tanaka, Takuya, Ishige, Yoko, Shionoya, Ikuyo, Yamamura, Kouichi, Sakuma, Takashi, Nishiki, Kazuaki, Nakase, Keisuke, Nojiri, Masafumi, Kato, Ryo, Shinomiya, Shohei, Fujimoto, Yuki, Oikawa, Taku, Mizuno, Shiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520810/ https://www.ncbi.nlm.nih.gov/pubmed/34409749 http://dx.doi.org/10.1111/1759-7714.14121 |
Ejemplares similares
-
Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2023) -
Differential response in patients with large cell neuroendocrine carcinoma of the lung to initial therapy: A case series
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022) -
Investigation of response factors for monotherapy with immune checkpoint inhibitors in non‐small cell lung cancer patients with PD‐L1 expression <50%
por: Takahara, Yutaka, et al.
Publicado: (2023)